Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) Amortization - Intangibles (2017 - 2024)

BeOne Medicines (BEIGF) has disclosed Amortization - Intangibles for 8 consecutive years, with $1.2 million as the latest value for Q2 2024.

  • Quarterly Amortization - Intangibles rose 526.06% to $1.2 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $9.0 million through Jun 2024, up 88.98% year-over-year, with the annual reading at $7.2 million for FY2023, 82.07% up from the prior year.
  • Amortization - Intangibles for Q2 2024 was $1.2 million at BeOne Medicines, down from $5.6 million in the prior quarter.
  • The five-year high for Amortization - Intangibles was $5.6 million in Q4 2023, with the low at $187000.0 in Q3 2020.
  • Average Amortization - Intangibles over 5 years is $964705.9, with a median of $188000.0 recorded in 2020.
  • The sharpest move saw Amortization - Intangibles crashed 43.5% in 2020, then soared 1112.83% in 2023.
  • Over 5 years, Amortization - Intangibles stood at $188000.0 in 2020, then soared by 335.64% to $819000.0 in 2021, then surged by 316.73% to $3.4 million in 2022, then soared by 63.4% to $5.6 million in 2023, then tumbled by 78.9% to $1.2 million in 2024.
  • According to Business Quant data, Amortization - Intangibles over the past three periods came in at $1.2 million, $5.6 million, and $2.3 million for Q2 2024, Q4 2023, and Q3 2023 respectively.